Start Date
April 30, 2022
Primary Completion Date
March 31, 2023
Study Completion Date
December 31, 2033
Intravenous Tislelizumab
Participants will receive 200mg, every three weeks for up to 51 weeks
Chemotherapy
Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
Fractionated radiation
Concurrent with chemo, x5 weeks
Esophagectomy
Surgical resection of cancer after chemoradiation therapy when no disease progression found.
University of Kentucky, Lexington
Collaborators (1)
BeiGene
INDUSTRY
University of Kentucky
OTHER
Zhonglin Hao
OTHER